SynthesisPeerJ2026
Role of fibroblast growth factor 23 in predicting CKD progression and prognosis: a systematic review and meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Chronic kidney disease (CKD) affects 10% of the global population. This meta-analysis evaluated fibroblast growth factor 23 (FGF-23) as a prognostic biomarker for CKD progression, kidney failure, cardiovascular events, and mortality. Materials and Methods: We systematically searched PubMed, Cochrane, Embase, and SCOPUS from inception through January 2025. Twelve prospective cohort studies enrolling 21,042 pre-dialysis adult patients with CKD stages 1-5 were included; outcomes encompassed kidney function decline, progression to kidney failure, cardiovascular events, heart failure, and all-cause mortality. Results: Elevated fibroblast growth factor (FGF)-23 levels were associated with lower estimated glomerular filtration rate (eGFR) (mean difference: 17.83 mL/min/1.73m Conclusions: FGF-23 is a significant prognostic biomarker predicting CKD progression, cardiovascular events, and mortality, supporting its utility in risk stratification and personalized management. Incorporating FGF-23 measurement into routine CKD care may enable earlier risk stratification and more targeted clinical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.